BIEL BioElectronics Corp.

BioElectronics Announces New Management Team

BioElectronics Announces New Management Team

FREDERICK, MD, Nov. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL), , is pleased to announce that after seeking legal counsel a Board of Directors and Company officers have been appointed/re-affirmed. These changes follow the unexpected passing of the Company’s founder, President and CEO Mr. Andrew Whelan, in October 2019.

Pursuant to Section 2 of Article III of BioElectronics Corporation's Bylaws, and as a prior requirement that the Board of Directors shall constitute three (3) directors, the individuals identified below have been appointed as a Director of the Corporation, each to hold such position:

Patricia A. Whelan: Chairman of the Board

Keith E. Nalepka: Executive Member

Kelly A. Whelan: Executive Member

Further, pursuant to Section 1 and Section 9 of Article V of the Corporation's bylaws adopted on February 27, 2001 the Board of Directors has appointed the individuals identified below to the office opposite his/her name, each to hold such office until the next annual meeting of the Board and until his/her successor is elected and qualified, or until his/her earlier death, resignation or removal:

John R. Martinez: Secretary; Vice President, Engineering

Keith E. Nalepka: Vice President, Sales

Kelly A. Whelan: Treasurer; President; Chief Executive Officer

Patricia A. Whelan: Chairman of the Board

Additionally, the individuals below have been engaged as consultants in a capacity opposite his/her name:

Richard Staelin, Ph.D.: Marketing, Clinical and Statistical Research

Kenneth J. McLeod, Ph.D.: Clinical and Engineering Research

Mr. Nalepka has more than 18 years of experience in the retail sales industry, both with large multi-million dollar brands and startups. Keith has long term relationships with retail buyers, corporate partners and key customers. He also worked to develop international distribution in Europe and the Middle East and South East Asia. Keith will continue to lead the Sales and Marketing efforts at BioElectronics. He is a graduate of the University of Maryland and spent several years with the Texas Rangers playing professional baseball. Keith also completed a Harvard Executive Management certificate program and was a Johns Hopkins Carey Business School Innovate Scholar winner selected by the National Science Foundation. "I am incredibly excited to join the Board and assist in guiding the overall direction and strategy of the business. We have reached a great transition point and are now poised to reap the benefits of closed international and domestic deals. We look forward to achieving additional FDA clearances and the final resolution of some regulatory roadblocks that have affected sales through the third quarter. I look forward to continuing to work with the great team of people at BioElectronics,” Mr. Nalepka stated.

Kelly Whelan has a degree in Business Management from the University of Maryland, University College and earned a certified public accountant's license in 2001. Ms. Whelan has spent the last 14 years as an independent consultant providing accounting, marketing and general business services. Prior to this she served as the Controller of Belfort Furniture, a northern Virginia based retailer that had sales of approximately 40 million dollars annually during her tenure. Ms. Whelan has also held various positions in accounting in the construction industry. "I am pleased to be leading the team at BioElectronics Corporation, to bring my late father's vision for the Company to fruition. We are moving forward in a swift but methodical manner. The focus of the Company is to quickly close good, solid deals and increase shareholder value,” Ms. Whelan said.

About BioElectronics Corporation

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit .

Contact:

Paul Knopick

 

940.262.3584
EN
15/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioElectronics Corp.

 PRESS RELEASE

Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corpor...

Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corporation FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation ( OTC: BIEL, a developer of medical technology products, today announces that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. "We are honored to welcome Sree Koneru to the Board. Sree brings a rich depth of experience in medical device developm...

 PRESS RELEASE

BioElectronics Corporation's Chairman Updates Investors

BioElectronics Corporation's Chairman Updates Investors Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD. Dear Shareholders, It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant. Current Medical (RecoveryRx) Sales Although our RecoveryRx product is well ac...

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of a Canine Arthr...

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study 96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via -- BioElectronics Corporation ( OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed ...

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of Pilot Study Re...

BioElectronics Corporation Announces the Publication of Pilot Study Results Beneficial Treatment Effect for Phantom and Residual Limb Pain Identified FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. "Treating intractable postamputation pain with wearable, non-invasive, non-thermal, pulsed shortwave (radiofrequency) therapy: a randomized, double-ma...

 PRESS RELEASE

BioElectronics Chairman Updates Investors

BioElectronics Chairman Updates Investors Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD. The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans.  As I have mentioned many times, I believe our strategic m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch